M1 KLINIKEN AG (M12.DE) Stock Fundamental Analysis
Europe - FRA:M12 - DE000A0STSQ8 - Common Stock
15.88 EUR
+0.82 (+5.44%)
Overall M12 gets a fundamental rating of 6 out of 10. We evaluated M12 against 27 industry peers in the Health Care Providers & Services industry. M12 gets an excellent profitability rating and is at the same time showing great financial health properties. M12 has a decent growth rate and is not valued too expensively. This makes M12 very considerable for quality investing!
1. Profitability
1.1 Basic Checks
M12 had positive earnings in the past year.
M12 had a positive operating cash flow in the past year.
In the past 5 years M12 has always been profitable.
M12 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of M12 (8.73%) is better than 96.30% of its industry peers.
M12 has a Return On Equity of 15.03%. This is in the better half of the industry: M12 outperforms 77.78% of its industry peers.
With an excellent Return On Invested Capital value of 13.44%, M12 belongs to the best of the industry, outperforming 92.59% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for M12 is in line with the industry average of 6.04%.
The last Return On Invested Capital (13.44%) for M12 is above the 3 year average (7.72%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.73% | ||
| ROE | 15.03% | ||
| ROIC | 13.44% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
1.3 Margins
M12 has a better Profit Margin (5.00%) than 81.48% of its industry peers.
In the last couple of years the Profit Margin of M12 has declined.
M12 has a better Operating Margin (8.52%) than 77.78% of its industry peers.
M12's Operating Margin has declined in the last couple of years.
M12 has a Gross Margin of 19.29%. This is comparable to the rest of the industry: M12 outperforms 40.74% of its industry peers.
In the last couple of years the Gross Margin of M12 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.52% | ||
| PM (TTM) | 5% | ||
| GM | 19.29% |
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so M12 is creating value.
The number of shares outstanding for M12 has been reduced compared to 1 year ago.
M12 has more shares outstanding than it did 5 years ago.
The debt/assets ratio for M12 is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 5.41 indicates that M12 is not in any danger for bankruptcy at the moment.
The Altman-Z score of M12 (5.41) is better than 100.00% of its industry peers.
M12 has a debt to FCF ratio of 0.70. This is a very positive value and a sign of high solvency as it would only need 0.70 years to pay back of all of its debts.
M12 has a Debt to FCF ratio of 0.70. This is amongst the best in the industry. M12 outperforms 100.00% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that M12 is not too dependend on debt financing.
M12 has a Debt to Equity ratio of 0.05. This is amongst the best in the industry. M12 outperforms 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 5.41 |
ROIC/WACC1.86
WACC7.23%
2.3 Liquidity
M12 has a Current Ratio of 2.06. This indicates that M12 is financially healthy and has no problem in meeting its short term obligations.
M12 has a Current ratio of 2.06. This is amongst the best in the industry. M12 outperforms 88.89% of its industry peers.
M12 has a Quick Ratio of 1.35. This is a normal value and indicates that M12 is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of M12 (1.35) is better than 77.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 10.36% over the past year.
The Earnings Per Share has been growing slightly by 7.97% on average over the past years.
The Revenue has been growing slightly by 6.52% in the past year.
The Revenue has been growing by 34.44% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
3.2 Future
Based on estimates for the next years, M12 will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.18% on average per year.
Based on estimates for the next years, M12 will show a quite strong growth in Revenue. The Revenue will grow by 8.24% on average per year.
EPS Next Y5.19%
EPS Next 2Y14.78%
EPS Next 3Y19.18%
EPS Next 5YN/A
Revenue Next Year6.09%
Revenue Next 2Y6.66%
Revenue Next 3Y6.53%
Revenue Next 5Y8.24%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 16.89, the valuation of M12 can be described as correct.
M12's Price/Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Earnings ratio of 26.11, M12 is valued a bit cheaper.
The Price/Forward Earnings ratio is 13.69, which indicates a correct valuation of M12.
M12's Price/Forward Earnings ratio is in line with the industry average.
When comparing the Price/Forward Earnings ratio of M12 to the average of the S&P500 Index (22.55), we can say M12 is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.89 | ||
| Fwd PE | 13.69 |
4.2 Price Multiples
M12's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. M12 is cheaper than 66.67% of the companies in the same industry.
The rest of the industry has a similar Price/Free Cash Flow ratio as M12.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.68 | ||
| EV/EBITDA | 7.68 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
M12 has a very decent profitability rating, which may justify a higher PE ratio.
M12's earnings are expected to grow with 19.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.26
PEG (5Y)2.12
EPS Next 2Y14.78%
EPS Next 3Y19.18%
5. Dividend
5.1 Amount
M12 has a Yearly Dividend Yield of 3.32%. Purely for dividend investing, there may be better candidates out there.
M12's Dividend Yield is rather good when compared to the industry average which is at 2.55. M12 pays more dividend than 92.59% of the companies in the same industry.
M12's Dividend Yield is a higher than the S&P500 average which is at 2.37.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.32% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
DPN/A
EPS Next 2Y14.78%
EPS Next 3Y19.18%
FRA:M12 (10/31/2025, 7:00:00 PM)
15.88
+0.82 (+5.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.8%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap311.88M
Revenue(TTM)354.98M
Net Income(TTM)17.74M
Analysts85
Price Target27.03 (70.21%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.32% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-4.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.89 | ||
| Fwd PE | 13.69 | ||
| P/S | 0.88 | ||
| P/FCF | 11.68 | ||
| P/OCF | 11.53 | ||
| P/B | 2.64 | ||
| P/tB | 11.36 | ||
| EV/EBITDA | 7.68 |
EPS(TTM)0.94
EY5.92%
EPS(NY)1.16
Fwd EY7.31%
FCF(TTM)1.36
FCFY8.56%
OCF(TTM)1.38
OCFY8.67%
SpS18.07
BVpS6.01
TBVpS1.4
PEG (NY)3.26
PEG (5Y)2.12
Graham Number11.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.73% | ||
| ROE | 15.03% | ||
| ROCE | 19.39% | ||
| ROIC | 13.44% | ||
| ROICexc | 18.99% | ||
| ROICexgc | 105.66% | ||
| OM | 8.52% | ||
| PM (TTM) | 5% | ||
| GM | 19.29% | ||
| FCFM | 7.52% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
ROICexc(3y)9.69%
ROICexc(5y)8.26%
ROICexgc(3y)31.7%
ROICexgc(5y)24.88%
ROCE(3y)11.15%
ROCE(5y)8.88%
ROICexgc growth 3Y38.16%
ROICexgc growth 5Y31.27%
ROICexc growth 3Y22.22%
ROICexc growth 5Y5.12%
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
F-Score9
Asset Turnover1.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.17 | ||
| Cap/Depr | 6.62% | ||
| Cap/Sales | 0.1% | ||
| Interest Coverage | 21.13 | ||
| Cash Conversion | 76.34% | ||
| Profit Quality | 150.51% | ||
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 5.41 |
F-Score9
WACC7.23%
ROIC/WACC1.86
Cap/Depr(3y)22.84%
Cap/Depr(5y)24.89%
Cap/Sales(3y)0.41%
Cap/Sales(5y)0.51%
Profit Quality(3y)272.44%
Profit Quality(5y)207.18%
High Growth Momentum
Growth
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
EPS Next Y5.19%
EPS Next 2Y14.78%
EPS Next 3Y19.18%
EPS Next 5YN/A
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
Revenue Next Year6.09%
Revenue Next 2Y6.66%
Revenue Next 3Y6.53%
Revenue Next 5Y8.24%
EBIT growth 1Y32.15%
EBIT growth 3Y30.31%
EBIT growth 5Y27.31%
EBIT Next Year31.44%
EBIT Next 3Y27.49%
EBIT Next 5YN/A
FCF growth 1Y132.58%
FCF growth 3Y27.23%
FCF growth 5YN/A
OCF growth 1Y108.94%
OCF growth 3Y24.88%
OCF growth 5YN/A
M1 KLINIKEN AG / M12.DE FAQ
Can you provide the ChartMill fundamental rating for M1 KLINIKEN AG?
ChartMill assigns a fundamental rating of 6 / 10 to M12.DE.
Can you provide the valuation status for M1 KLINIKEN AG?
ChartMill assigns a valuation rating of 4 / 10 to M1 KLINIKEN AG (M12.DE). This can be considered as Fairly Valued.
How profitable is M1 KLINIKEN AG (M12.DE) stock?
M1 KLINIKEN AG (M12.DE) has a profitability rating of 7 / 10.
What are the PE and PB ratios of M1 KLINIKEN AG (M12.DE) stock?
The Price/Earnings (PE) ratio for M1 KLINIKEN AG (M12.DE) is 16.89 and the Price/Book (PB) ratio is 2.64.